Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive NSCLC”

159 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 159 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07330076
What this trial is testing

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Early research (Phase 1)Study completedNCT02292550
What this trial is testing

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableStudy completedNCT03271554
What this trial is testing

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 355
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Testing effectiveness (Phase 2)Active Not RecruitingNCT03737994
What this trial is testing

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Not applicableNot Yet RecruitingNCT06644495
What this trial is testing

Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

Who this might be right for
NSCLC
Qilu Pharmaceutical Co., Ltd. 1,000
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Testing effectiveness (Phase 2)UnknownNCT03215693
What this trial is testing

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 152
Not applicableUnknownNCT04499794
What this trial is testing

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Who this might be right for
Untreated Advanced NSCLC PatientsFISH Identified ALK Fusion Positive or Negative
Chinese Academy of Medical Sciences 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Testing effectiveness (Phase 2)Study completedNCT02450903
What this trial is testing

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Not applicableLooking for participantsNCT05735327
What this trial is testing

Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 50
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Large-scale testing (Phase 3)Active Not RecruitingNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Not applicableUnknownNCT04317651
What this trial is testing

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerAdvanced CancerMetastatic Cancer
Fondazione Ricerca Traslazionale 500
Load More Results